

Prior Authorization Request Form for Erythropoiesis Stimulating Agents

FAX this completed form to (844) 205-3386

<u>OR</u> Mail requests to: PA Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720

OR Prior authorization may be completed at https://www.covermymeds.com/main/prior-authorization-forms/

I. PROVIDER INFORMATION		II. MEM	IBER INFOR	MATION
Prescriber Name:		Member Name:		
Prescriber Specialty:		Identification #:		
Office Contact Name:		Group #:		
Group Name:		Date of Birth:		
Fax #:		Medication Allergies:		
Phone #:				
III. DRUG INFORMATION (One dru	g request per for	m)		
Drug name and strength: Dosage Interval (sig):		ig):	Qty. per Day:	
IV. REQUIRED DOCUMENTION (Det item must be submitted with prior			umentation	demonstrating evidence for each
Specify diagnosis & diagnosis code relevant to this request: Dx/Dx Code:				
Does the member have a history of a contraindication to the requested medication?			□ Yes	
			🗆 No	
Requests for all non-preferred Erythropoiesis Stimulatin Agents : Does the member have a history of trial and failure of contraindication or intolerance to the preferred Erythropoie Stimulating Agents? <i>Refer to <u>https://papdl.com/preferred-dr</u> a list of preferred and non-preferred medications in this class.</i>		of or esis r <u>ug-list</u> for	∐ Yes	Medication Taken Previously (start and end date and dose):
☐ If requesting for daily quantity e <u>Services/Pages/Quantity-Limits</u> information:				
specialist, nephrologist, surgeon,	g specialist, (e.g., her etc) please indicate or other causes of a /L and serum trans on therapy: ted with chronic kid er patients on chem n <10g/dL suppressive chemot zidovudine in meml n <10g/dL evel ≤500mUnits/n	matologist a speciali nemia (e.g ferrin satu dney disea otherapy, herapy an bers with l	:/oncologist, g st consulted:_ g, iron deficie: uration ≥ 20% use, has pretre both of the fo d the anticipa	ncy, hemolysis, vitamin B12 deficiency, :
For a reduction of allogeneic blocHas pretreatment hemoglobi			ents, both of t	he following:

□ Is undergoing elective, noncardiac, nonvascular	surgery				
RENEWAL REQUIEST:	0,				
One of the following:					
Experienced an increase in hemoglobin comp	pared to baseline				
□ Is prescribed an increased dose of the reques		(A) consistent with			
FDA-approved package labeling, nationally re					
□ One of the following:	cognized compendia, or peer reviewed in				
□ Has serum ferritin ≥ $100mcg/L$ and serum tra	ansferrin saturation > 20%				
□ Is receiving supplemental iron therapy					
□ For a diagnosis of anemia associated with chron	ic ronal disease has one of the following:				
\square Hemoglobin ≤ 10 g/dL for members not on di					
$\square Hemoglobin \le 10g/dL for members on dialys$	-				
□ For a diagnosis of anemia in cancer patients on chemotherapy, has hemoglobin $\leq 12g/dL$					
□ For a diagnosis of anemia due to zidovudine in members with HIV infection, all of the following:					
Has pretreatment hemoglobin <12g/dL					
☐ Has a serum erythropoietin level ≤500mUnits/n					
☐ Is receiving a dose of zidovudine ≤4200mg/wee	K				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
TV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
TV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERT	INENT CLINICAL INFORMATION :				
		Date			
Appropriate clinical information to support the request on the basis of medical necessity must be submitted.	Provider Signature:	Date:			

PA Department will respond via fax or phone within 24 hours. Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)